Center for Energy Studies Wed, Dec. 13, 2023 | 8 am - 10 am Oil Market Update and Prospects for 2024 See Details
Center for Health and Biosciences | Science and Technology Policy Fri, Feb. 09 - Sat, Feb. 10, 2024 | 8 am - 8 pm Brave New Worlds — Who Decides? Research, Risk, and Responsibility See Details
U.S. Health System Transformation | Center for Health and Biosciences | Journal Market Spiral Pricing of Cancer Drugs September 3, 2013 | Donald Light, Hagop M. Kantarjian toggle sidebar Toggle Sidebar Table of Contents Author(s) Donald Light Edmond J. Safra Center for Ethics, Harvard University Hagop M. Kantarjian Nonresident Fellow in Health Policy Share this Publication Facebook Twitter Email Linkedin Print This Publication Abstract High patented cancer drug prices are not related to the high cost of development or to the relative benefit of individual drugs over available ones. Several steps could be implemented to reduce these high prices to more acceptable ones. Read the full article in Cancer. Print This Publication Share Facebook Twitter Email Linkedin Related Research Center for Health and Biosciences | Issue Brief Destigmatizing Mental Health and Cultivating Resilience Read More Center for Health and Biosciences | Working Paper Brain Capital’s Role in US-China Competition Read More Center for Health and Biosciences | Issue Brief Ensuring Understanding: Language-Concordant Discharge Instructions Read More Back to top
Center for Health and Biosciences | Issue Brief Destigmatizing Mental Health and Cultivating Resilience Read More
Center for Health and Biosciences | Working Paper Brain Capital’s Role in US-China Competition Read More
Center for Health and Biosciences | Issue Brief Ensuring Understanding: Language-Concordant Discharge Instructions Read More
